Analysts at Leerink Partnrs lifted their FY2026 earnings estimates for Travere Therapeutics in a research report issued to ...

Investment analysts at Leerink Partnrs upped their FY2026 EPS estimates for shares of AstraZeneca in a note issued to ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00.

Schrodinger Inc (SDGR) stock saw a modest uptick, ending the day at $24.34 which represents a slight increase of $3.01 or 14.11% from the prior close of $21.33. The stock opened at $21.52 and touched ...

During his presentation at the J.P. Morgan Healthcare Conference last week, Incyte CEO Hervé Hoppenot took investors on a ...

In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and ...

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...

Beta Bionics (BBNX), a maker of insulin delivery devices, has disclosed terms for an upsized $113M initial public offering.

Despite a 15% drop in the SPDR S&P Biotech ETF, insider buying presents opportunities. Read why these small and mid-cap ...

Immunic Inc (IMUX) stock saw a modest uptick, ending the day at $0.95 which represents no change from the prior close of of $0.95. The stock opened at $0.98 and touched a low of $0.92 during the day, ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.